Titre:
  • Intratumoral administration of the immunologic adjuvant AS01 B in combination with autologous CD1c (BDCA-1) + /CD141 (BDCA-3) + myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma
Auteur:Tijtgat, Jens; Geeraerts, Xenia; Boisson, Anaïs; Stevens, Latoya; Vounckx, Manon; Dirven, Iris; Schwarze, Julia Katharina; Raeymaeckers, Steven; Forsyth, Ramses; Van Riet, Ivan; Tuyaerts, Sandra; Willard-Gallo, Karen; Neyns, Bart
Informations sur la publication:Journal for ImmunoTherapy of Cancer, 12, 1, e008148
Statut de publication:Publié, 2024-01
Sujet CREF:Généralités
Mots-clés:Adjuvants, Immunologic
Dendritic Cells
Immunohistochemistry
Melanoma
Therapies, Investigational
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:2051-1426
info:doi/10.1136/jitc-2023-008148
info:scp/85182098239
info:pmid/38212127